Thymosin Beta-4 Protects the Heart from Damage and Scarring After a Heart Attack in Mice

Researchers first measured thymosin β4 levels in heart tissue from mice with acute heart attacks using qRT-PCR, immunohistochemistry, and Western blot. They then delivered exogenous thymosin β4 via intraperitoneal injection of adeno-associated virus (AAV-Tβ4) to mice with surgically induced heart attacks. Cardiac function was assessed alongside tissue staining (HE and Masson) to evaluate inflammation and fibrosis. In parallel, they tested thymosin β4's effects on isolated mouse cardiac myocytes exposed to hydrogen peroxide stress and on myofibroblasts stimulated with TGF-β1.

Heart attacks are a leading cause of death worldwide, and the scarring that follows often leads to heart failure. Current treatments focus on restoring blood flow but do little to prevent the fibrosis that weakens the heart over time. Thymosin β4's ability to simultaneously fight inflammation, reduce oxidative damage, and block scar formation addresses multiple aspects of post-heart attack damage — making it an attractive candidate for future cardiac therapies.

Thymosin β4 is one of the most studied peptides in regenerative medicine, with previous research showing protective effects in wound healing, corneal repair, and neurological injury. This study extends its potential to cardiac fibrosis specifically — a condition with few effective treatments. If these findings translate to humans, thymosin β4 could join a growing class of peptide therapies aimed at repairing tissue damage rather than just managing symptoms.

This was a mouse study, and the cardiovascular system in mice differs from humans in important ways. The study did not report specific group sizes or long-term follow-up beyond the acute and fibrotic phases. The gene therapy delivery method (AAV) may not be the most practical clinical approach. No dose-response data were provided, and the exact signaling pathways require further characterization.